when were glp 1 agonists approved Evolution of GLP‐1 Receptor for Diabetes Treatment Oral Small-Molecule GLP-1 Receptor Agonists:

As with other complex diseases, the next era likely involves precision, combination therapypairing antiamyloid agents with treatments aimed at metabolic, inflammatory, vascular, and synaptic pathways

Read on!

odds ratio 3.3536.97), rates of pulmonary aspiration (0.1% to 0.2%) remain quite low, with no significant increase in comparison to control groups

and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal

Individuals interested in supporting gut microbiome balance and metabolic wellness may consider targeted probiotic supplements